Over 280 million people worldwide have depression, and roughly one-third do not respond adequately to conventional antidepressants. Ozone therapy targets neuroinflammation and oxidative stress, two mechanisms increasingly linked to treatment-resistant depression. Animal studies show ozone modulates brain cytokines and serotonin pathways. But human clinical data is essentially nonexistent: no published RCTs have tested ozone therapy for depression.
This article covers how ozone therapy is proposed to work for depression, what the current evidence shows, and how it compares to oxygen therapy for depression, including hyperbaric oxygen therapy (HBOT).
The Neuroinflammation Theory of Depression
The link between inflammation and depression is well-established in psychiatric research. Patients with major depressive disorder consistently show elevated inflammatory markers, including C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha).4
Inflammation affects the brain through several pathways:
- Tryptophan diversion. Inflammation activates the enzyme indoleamine 2,3-dioxygenase (IDO), which diverts tryptophan away from serotonin production and toward kynurenine, a neurotoxic metabolite.
- Blood-brain barrier disruption. Chronic inflammation increases blood-brain barrier permeability, allowing peripheral inflammatory signals to reach the brain.
- Microglial activation. Neuroinflammation activates microglia (the brain’s immune cells), which release inflammatory cytokines that damage neurons and impair neuroplasticity.
- Reduced BDNF. Inflammation suppresses brain-derived neurotrophic factor (BDNF), a protein critical for neuroplasticity, neurogenesis, and mood regulation.
This framework is the basis for ozone therapy’s proposed application in depression: if ozone can reduce systemic inflammation, the downstream effects on the brain could theoretically improve depressive symptoms.
How Ozone Therapy Might Affect Depression
Ozone therapy’s proposed mechanisms for depression include:
| Mechanism | How It Works | Relevance to Depression |
|---|---|---|
| Anti-inflammatory modulation | Ozone activates Nrf2 pathway, upregulates antioxidant enzymes, reduces NF-kB-driven inflammation | May reduce the systemic inflammation linked to depression |
| Improved oxygenation | Increases 2,3-DPG in red blood cells, improving oxygen release to tissues including the brain | Brain hypoperfusion is observed in depressed patients |
| Oxidative preconditioning | Low-dose oxidative stress trains cells to handle future oxidative challenges | May protect neurons from oxidative damage implicated in depression |
| Mitochondrial support | Ozone may improve mitochondrial function and ATP production | Mitochondrial dysfunction is increasingly linked to treatment-resistant depression |
What Does the Research Say?
The evidence for ozone therapy in depression is limited to preclinical studies and indirect clinical observations:
- Animal studies. Rodent models of depression show that ozone exposure can reduce neuroinflammation markers and improve depression-like behaviors (immobility time in forced swim tests, sucrose preference). These studies provide mechanistic plausibility but do not translate directly to human outcomes.2
- Indirect clinical evidence. Patients receiving ozone therapy for other conditions (chronic pain, autoimmune disorders, chronic infections) sometimes report mood improvements. These are anecdotal and confounded by the improvement in their primary condition.
- No human clinical trials. As of the latest available literature, no published randomized controlled trials have tested ozone therapy for major depressive disorder, bipolar depression, or treatment-resistant depression.
“The neuroinflammation hypothesis provides a plausible rationale for ozone therapy in depression, but plausible mechanisms and proven clinical benefit are two very different things. No human clinical trials have tested this application.”
Ozone Therapy vs. HBOT for Depression
Hyperbaric Oxygen Therapy (HBOT) delivers 100% oxygen at increased atmospheric pressure. While both therapies aim to improve oxygenation and reduce inflammation, HBOT has a significantly stronger evidence base for depression.
| Factor | Ozone Therapy | HBOT |
|---|---|---|
| Human clinical trials for depression | None published | Multiple, including sham-controlled RCTs |
| Strongest evidence | Animal models only | Post-stroke and post-TBI depression (RCT data) |
| Biomarker evidence | None in depression context | BDNF and NGF increases correlated with symptom improvement3 |
| Cost per session | $100-300 | $200-400 |
| Typical protocol | 10-20 sessions (no established protocol) | 20-40 sessions (emerging protocols from trials) |
| FDA status | Not approved for depression | Not approved for depression |
A sham-controlled RCT by Tang et al. demonstrated that HBOT significantly reduced depression scores in post-stroke patients at both 2 and 4 weeks, with improvements correlated to increases in brain-derived neurotrophic factor (BDNF).3 A systematic review of 6 RCTs found HBOT consistently reduced depressive symptoms across multiple study populations.5 Ozone therapy has no comparable evidence.
Cost and Practical Considerations
Ozone therapy for depression is not covered by insurance. Out-of-pocket costs vary by modality:
- Major autohemotherapy (MAH): $150-300 per session
- Rectal insufflation: $75-150 per session
- IV ozone: $200-400 per session
- 10-pass ozone: $750-1,500 per session
A typical protocol of 10-20 sessions would cost $1,000-6,000 depending on the modality. There are no established dose-response relationships or standardized protocols for depression, so treatment plans vary entirely by practitioner.
Safety
Ozone therapy carries specific risks depending on the delivery method. Ozone should never be inhaled directly, as it is a potent respiratory irritant. IV ozone carries rare but serious risks of air embolism. MAH and rectal insufflation are generally well-tolerated when performed by trained practitioners.
For patients with depression, it is critical to continue any current psychiatric medications and not substitute ozone therapy for evidence-based treatments. Abruptly discontinuing antidepressants can cause withdrawal symptoms and relapse.
The Bottom Line
Ozone therapy for depression has a plausible biological rationale based on the neuroinflammation hypothesis, but no human clinical trials support its use. The mechanisms are real: ozone does modulate inflammation, improve oxygenation, and activate antioxidant defenses. Whether these effects translate to meaningful improvement in depressive symptoms remains unknown.
If you are interested in oxygen-based therapies for depression, HBOT has a stronger evidence base, particularly for depression secondary to stroke or traumatic brain injury. For primary depression, evidence-based treatments including psychotherapy, antidepressants, exercise, and emerging options like ketamine and TMS should be the first line of treatment.
Related Articles
References
- Bocci V, Valacchi G. Nrf2 activation as target to implement therapeutic treatments. Front Chem. 2015;3:4. DOI: 10.3389/fchem.2015.00004
- Delgado-Roche L, Riera-Romo M, Mesta F, et al. Medical ozone promotes Nrf2 phosphorylation reducing oxidative stress and pro-inflammatory cytokines in multiple sclerosis patients. Eur J Pharmacol. 2017;811:148-154. DOI: 10.1016/j.ejphar.2017.06.017
- Tang M, Zhang S, Chen J, et al. Hyperbaric Oxygen Therapy Upregulates Neurotrophic Factors to Ameliorate Post-Stroke Depression. Neuropsychiatr Dis Treat. 2026. DOI: 10.2147/ndt.s573494
- Dowlati Y, Herrmann N, Swardfager W, et al. A Meta-Analysis of Cytokines in Major Depression. Biol Psychiatry. 2010;67(5):446-457. DOI: 10.1016/j.biopsych.2009.09.033
- Ahsan M, et al. Efficacy of hyperbaric oxygen therapy in the treatment of depression. Systematic review. 2026.
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
